Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis.
10.1007/s11655-022-2884-5
- Author:
Xiao-Nan ZHANG
1
;
Yan-Yang LI
2
;
Yuan-Hui ZHANG
3
;
Wan-Qin ZHANG
3
;
Ya-Ping ZHU
3
;
Jun-Ping ZHANG
3
;
Shi-Chao LV
3
;
Long-Tao LIU
4
Author Information
1. National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
2. Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
3. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300112, China.
4. National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. liulongtao1976@126.com.
- Publication Type:Systematic Review
- Keywords:
Shengmai San;
anthracyclines;
cardiotoxicity;
meta-analysis;
systematic review
- MeSH:
Anthracyclines/adverse effects*;
Cardiotoxicity/etiology*;
Drug Combinations;
Drugs, Chinese Herbal/adverse effects*;
Humans
- From:
Chinese journal of integrative medicine
2022;28(4):374-383
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To systematically evaluate the efficacy of Shengmai San in patients with cardiotoxicity of anthracyclines.
METHODS:Randomized controlled trials (RCTs) were identified by searching China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), PubMed, Cochrane Library, and Embase Databases from the inceptions until December 2020. The Cochrane Handbook was used to evaluate the risk of bias in the included studies. Data analysis was conducted using RevMan 5.3 software.
RESULTS:Totally 19 RCTs with 2,331 participants were included in this review. Results showed that in improving arrhythmia (13 RCTs, n=1,877, RR=0.37, 95%CI 0.25 to 0.52, P<0.00001), the treatment group was superior to the control group. In terms of reducing left ventricular end-diastolic diameter (LVEDD, 2 RCTs, n=128, MD=-0.79, 95%CI -0.93 to -0.65, P<0.00001) and left ventricular end systolic diameter (LVESD, 2 RCTs, n=128, MD=-0.58, 95%CI -0.82 to -0.35, P<0.00001), the treatment group was also better than the control group. In reducing myocardial enzymes such as creatine kinase (CK) [(3 RCTs, n=256, SMD=-0.80, 95%CI -1.16 to -0.44, P<0.0001), (2 RCTs, n=126, SMD=-0.62, 95%CI -0.98 to -0.26, P=0.0007)], the treatment group was superior to the control group.
CONCLUSION:Shengmai San has a positive effect on the treatment of cardiotoxicity from anthracyclines. However, in the future, it is still necessary to conduct high-quality RCTs to verify its efficacy.
